Gilead Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Three acquisitions—Tubulis, Ouro, and Arcellx—strengthen the pipeline in oncology, inflammation, and virology, with each bringing differentiated assets and platforms. Deals are financially disciplined, expected to close in Q2 2026, and aim for rapid integration and future growth.
-
Strong 2025 performance was driven by major launches and disciplined expenses, with a robust pipeline and up to eight new products expected in the next two years. Strategic acquisitions like Arcellx expand oncology and cell therapy capabilities, while HIV prevention and treatment markets are shifting toward long-acting therapies.
-
Long-acting HIV therapies and a 12-month PrEP are advancing, with pivotal data expected by 2027. Expansion of Livdelzi could double its patient base, while the Arcellx acquisition and in vivo CAR T investments position the company for durable growth in oncology and cell therapy.
-
2026 guidance targets mid-single digit growth, led by HIV and PrEP franchises, with Biktarvy and Yeztugo as key drivers. Oncology expands with Arcellx acquisition and Trodelvy's first-line potential, while inflammation grows via seladelpar and a promising pipeline.
-
Management highlighted strong HIV franchise growth, robust pipeline launches through 2027, and disciplined financial returns. Yes2Go and Descovy are driving prevention market gains, while new oncology and HIV treatments are set for near-term launches. Operating margins and shareholder returns remain top-tier.
Fiscal Year 2025
-
Delivered strong 2025 results with 6% HIV and liver growth, robust HIV prevention momentum, and four major launches planned for 2026. Guidance calls for 4%-5% base business growth, 6% HIV growth, and $800M Sunlenca revenue, with continued shareholder returns and a strong pipeline.
-
The discussion highlighted advances in long-acting HIV therapies, prioritization of new integrase inhibitors, and expansion into inflammation and cell therapy. Next-generation CAR-Ts and in vivo approaches are being developed, with key data readouts expected in the coming year.
-
Long-acting HIV prevention injectables are driving rapid market growth, with strong early adoption and payer coverage. The pipeline is robust in both HIV and oncology, supported by disciplined business development and operational efficiency, positioning for sustained top-line and EPS growth.
-
Base revenues and R&D investment are driving strong growth, with new launches like Yeztugo showing high efficacy and rapid uptake. M&A focuses on synergistic, late-stage assets, while China is now a key innovation source. Cell therapy and HIV pipeline advances support long-term expansion.
-
Constructive policy engagement and a $32B US investment underpin strong HIV and liver franchise growth. Yeztugo's rapid launch and access, robust HIV and oncology pipelines, and selective BD strategy position the business for continued expansion.
-
Strong Q3 results driven by HIV and liver portfolios, with Biktarvy, Descovy, and Livdelzi leading growth. Yeztugo launch exceeded expectations, achieving rapid payer coverage. Full-year guidance raised for HIV and total product sales, while cell therapy faces ongoing headwinds.
-
Cell therapy access has expanded to community settings, with improved manufacturing and strong commercial performance. Anito-cel is on track for a 2026 launch in multiple myeloma, and new in vivo CAR-T technology promises broader, lower-cost access. FDA regulatory changes and robust pipeline developments support future growth.
-
Portfolio diversification is accelerating with robust HIV, oncology, and inflammation pipelines. Lenacapavir and Descovy are driving PrEP market growth, while policy and reimbursement strategies support access. Multiple launches and clinical readouts are expected through 2033.
-
Strong Q2 results and a successful Sunlenca launch are driving growth in HIV prevention and treatment, with high market awareness and expanding payer coverage. The pipeline is robust, with multiple HIV and oncology launches expected, and strategic acquisitions like CymaBay are reinforcing diversification and future growth.
-
A clear focus on virology, oncology, and inflammation drives a diverse pipeline, with key HIV and oncology trials progressing and new CAR-T and immunology assets in development. Notable updates include ARTISTRY and PURPOSE studies, Trodelvy expansion, and anito-cel's path to market.
-
Second quarter saw strong growth in HIV, oncology, and liver disease, highlighted by the successful launch of YEZTUGO and robust sales of BIKTARVY and DESCOVY. Full-year guidance was raised for revenue and EPS, with continued momentum expected in key therapeutic areas.
-
Key growth areas include HIV, oncology, and inflammation, with imminent launch of lenacapavir for PrEP and robust late-stage pipelines. Trodelvy is poised to become a new standard in breast cancer, while cell therapy and global expansion drive future opportunities.
-
Key pipeline advances include imminent lenacapavir launch for HIV prevention, strong TRODELVY data in first-line triple-negative breast cancer, and promising anito-cel CAR-T results. Early-stage immunology assets and next-generation cell therapies are also progressing.
-
Key pipeline advances include imminent lenacapavir launch for HIV prevention, strong TRODELVY data in first-line triple-negative breast cancer, and promising Anito-cel CAR-T results for myeloma. Early-stage immunology and rheumatology programs are progressing, with multiple launches anticipated.
-
The discussion highlighted a robust pipeline with imminent launches in HIV and oncology, a strong focus on diversification, and strategic use of AI for efficiency. The company is well-positioned against industry headwinds due to its U.S.-centric IP, disciplined capital allocation, and proactive approach to healthcare reform.
-
Anito-cel demonstrates high response rates and a strong safety profile, supporting its potential as an outpatient therapy for myeloma. Manufacturing advances and a growing global footprint position the product for a 2026 launch, while next-gen CAR-T constructs and solid tumor programs expand the pipeline.
-
Disciplined execution and scenario planning underpin growth despite regulatory uncertainty. Lenacapavir's launch is set to transform HIV prevention, with flexible access models and a strong switch strategy. Biktarvy maintains robust growth and market leadership.
-
The meeting covered strong 2024 financial results, robust pipeline progress, and the election of all director nominees. All shareholder proposals were rejected, and management addressed questions on compliance, innovation, and global access to medicines.
-
Base business grew 4% year-over-year, led by HIV and liver disease, while total product sales declined 1% due to lower VEKLURY sales. Strong operating margin and EPS were reported, with multiple launches ahead, including lenacapavir for PrEP and Trodelvy in new indications.
-
Anito-cel BCMA CAR-T demonstrates strong efficacy and safety, with a 2026 launch planned and a focus on rapid manufacturing and global expansion. Outpatient delivery and modular accreditation are key to broader access, while next-gen bispecific CAR-Ts and autoimmune indications are advancing.
-
Strong 2024 growth is expected to continue, with 2025 temporarily impacted by policy and FX headwinds. Lenacapavir PrEP's mid-2024 launch aims to transform HIV prevention, while targeted market expansion and new product launches in HIV, liver, and oncology support a robust outlook.
-
Management outlined a strategy focused on sustained HIV leadership, rapid expansion in long-acting treatments, and diversification into oncology and inflammation. Financial discipline, robust cash flow, and a strong pipeline support growth and shareholder returns.
Fiscal Year 2024
-
Strong 2024 results with 8% growth in core product sales, led by HIV, oncology, and liver disease. 2025 guidance reflects Medicare Part D and FX headwinds, but underlying demand remains robust, with key launches and pipeline progress expected to drive future growth.
-
The event highlighted strong momentum in HIV prevention with lenacapavir's anticipated 2025 launch, ongoing innovation in HIV treatment, and robust oncology growth driven by cell therapy and Trodelvy. Financial guidance points to mid-single digit growth, with legal and regulatory matters well managed.
-
All major business franchises are growing, with no major patent cliffs through 2033. Lenacapavir's strong prevention data and launch strategy target significant PrEP market expansion, while new HIV treatments and cell therapies are poised for multiple launches. Trodelvy and Livdelzi offer further growth in oncology and liver disease.
-
Management highlighted robust growth in HIV, oncology, and liver disease, with minimal patent risk until 2033. Lenacapavir is set to transform the PrEP market, while new long-acting HIV treatments and promising oncology and liver assets drive future growth.
-
Q3 saw 7% year-over-year growth in total product sales, strong HIV and oncology performance, and raised 2024 guidance for revenue, operating income, and EPS. Key launches and pipeline advances, including lenacapavir and Livdelzi, exceeded expectations.
-
Leadership in HIV continues with Biktarvy and a robust pipeline, while lenacapavir's 100% efficacy in PrEP could transform prevention. Livdelzi's launch targets a rare liver disease with a differentiated profile, and Trodelvy is expanding in breast and other cancers.
-
A five-year transformation has diversified the portfolio, with strong growth in HIV, liver disease, and oncology. Lenacapavir for PrEP and new long-acting HIV treatments are set to expand markets, while operational leverage and disciplined capital allocation support financial strength.
-
The event highlighted strong growth in virology, oncology, and liver disease, with lenacapavir poised to transform HIV prevention and a robust pipeline of next-generation HIV and cell therapy products. Seladelpar's launch is expected to drive liver franchise growth, while business development will focus on synergistic, late-stage deals.
-
Q2 2024 saw robust growth in HIV, liver disease, and oncology, with total product sales up 5% year-over-year and strong bottom-line performance. Raised full-year guidance for operating income and EPS, highlighted by clinical milestones in HIV prevention and imminent seladelpar launch.
-
The business is advancing its transformation with strong virology and oncology growth, expanding its clinical pipeline, and targeting 1/3 of revenue from oncology by 2030. Long-acting HIV therapies and cell therapy innovations are key drivers, while M&A will focus on smaller, strategic deals.
-
The company is advancing a diversified pipeline, with HIV as a core strength and significant progress in oncology, especially with Trodelvy and TIGIT. Key data readouts for lung and breast cancer, as well as six-month HIV regimens, are expected in late 2024 and 2025.